AVITA Medical
Corporate Fact Sheet

AVITA Medical (ASX: AVH, NASDAQ: RCEL) is a regenerative medicine biotech company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration. AVITA Medical is advancing the standard of care for burn patients with its novel technology platform, the RECELL® System. The company's proprietary technology provides innovative treatment solutions derived from the skin's own regenerative properties.

The RECELL® System

AVITA Medical's first product, the RECELL System, is approved by the FDA for the treatment of severe thermal burns in patients 18 years of age and older, and enables medical professionals to collect cells from a small sample of a patient's own skin to create a suspension of Spray-On Skin™ Cells that are necessary to regenerate the outer layer of natural, healthy skin. The cellular suspension is prepared at the point of care in as little as 30 minutes, and the Spray-On Skin Cells are applied directly on a second-degree burn or with an expanded skin graft on a third-degree burn, allowing for broad and even distribution of live cells across the entire wound bed to facilitate healing across the whole wound.

The RECELL System is the first FDA-approved treatment for burn care in 20 years, representing a major advancement with benefits in both clinical outcomes and cost savings. Compelling data from randomized, controlled clinical trials conducted at leading U.S. burn centers and real-world use of the RECELL System demonstrate:

- Minimal skin requirements – Second degree burn injuries required 97.5% less donor skin[i] (a credit card size skin sample can treat an entire adult back) and third degree burns required 32% less donor skin.[ii] With reduced donor site size required to treat burns with the RECELL System, there is:
    - Improved donor site healing – Donor sites were more likely to heal at one and two weeks with twice as many wounds healing at week one.[i]
    - Improved patient satisfaction – Superior donor site scar outcomes and less pain.[i]
- Cost effectiveness – On average, burn centers utilizing the RECELL System can reduce overall costs associated with the care of patients with severe burn injuries.[iii]
    - 30% reduction in length of stay – fewer procedures gets patients home sooner
    - 35% fewer procedures -- reduced donor size and greater meshing ratio enables permanent closure with fewer invasive autograft procedures
    - 35% cost savings – shorter and fewer procedures, decreased length of stay, and reduced resource use translates in burn center savings
- RECELL saves money in all in-patient scenarios where the total burn surface area is >10%.[iii]

Established facility and physician reimbursement codes make the RECELL System accessible to treat burn patients in hospital and outpatient settings, as well as ambulatory surgery centers.

Focused Pipeline with Strong Growth Potential

AVITA Medical is currently exploring the potential of its novel technology platform to harness the regenerative properties of a patient's own skin across a number of dermatological indications. Supported by a substantive body of clinical evidence with patients internationally and peer-reviewed publications, the company's late stage pipeline is focused on injuries and skin defects leveraging the RECELL System. Additionally, AVITA Medical is in the early research stages of assessing the RECELL System as a delivery platform to help address cellular and genetic disorders.

Injuries		
Soft Tissue Reconstruction	Acute full-thickness skin defects that require soft tissue reconstruction can include abrasions, lacerations, surgical wounds, degloving (a type of injury where the skin is ripped from the underlying tissue) and crush wounds (a break in the external surface of the body).	Pivotal First patient enrolled March 2020 in trial evaluating the safety and effectiveness of the RECELL System in combination with meshed autografting for patients undergoing reconstruction of skin defects not associated with a burn injury
Pediatric Scalds **Pediatric Donor Sites**	In the U.S., it is estimated that 30 percent of burn patients are within the ages of one to 15 years old, and approximately 45 percent of the pediatric burn injuries are from scald burns.[iv] Superiority study on healing time of donor sites for RECELL-treated split-thickness donor sites vs standardized dressings only	Pivotal (Scalds) First patient enrolled March 2020 in trial seeking to demonstrate that treatment with the RECELL System of partial-thickness burn injuries within 72 hours can safely and effectively increase the incidence of healing at day 10 when compared to a standard wound dressing in pediatric patients Pivotal (Donor Sites) First patient enrolled October 2018
Defects		
Vitiligo	Vitiligo is a disease affecting approximately 6.5 million people in the U.S. resulting in loss of color, or pigmentation, in patches of skin that impacts the quality of life for those living with the condition[v,vi]	Feasibility Received FDA IDE approval in December 2019 for a feasibility study to primarily determine the optimal concentration of the cell suspension prepared using the RECELL System
Genetic Errors		
Epidermolysis Bullosa (EB)	EB is a group of rare and incurable skin disorders caused by mutations in genes encoding structural proteins resulting in skin fragility and blistering, leading to	Early Stage Research Entered into sponsored research agreement with the Gates Center for Regenerative Medicine at the University

	chronic wounds and, in some sub-types, an increased risk of squamous cell carcinoma or death	of Colorado in November 2019 to focus on proof-of-concept and development of a spray-on treatment of genetically modified cells for EB patients with potential applicability to other genetic skin disorders
Dermatology		
Rejuvenation	More than 3 million aesthetic procedures are performed in the U.S. annually aimed to improve skin tightness, texture, and evenness in skin tone	Early Stage Research Engaged in discussions for a rejuvenation sponsored research agreement

Management Team

- Dr. Michael Perry, Chief Executive Officer
- David McIntyre, Chief Financial Officer
- Erin Liberto, Chief Commercial Officer
- Andrew Quick, Chief Technology Officer
- Donna Shiroma, General Counsel

Key Financials

For fiscal year 2019 (July 1, 2018 – June 30, 2019), AVITA Medical reported:

- Total revenue of A$17.0 million, reflecting an increase of 50% year-over-year
- U.S. product sales of A$6.2 million

In AVITA Medical's half-year financial report for fiscal 2020 (six months ended Dec. 31, 2019), the company reported:

- Total revenue of A$13.5M
- U.S. product sales of A$9.3M

To learn more, visit www.avitamedical.com

U.S. Media **Sam Brown, Inc.** Christy Curran Phone +1 615 414 8668 christycurran@sambrown.com **O.U.S Media** **Monsoon Communications** Rudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au	**Investors** **Westwicke Partners** Caroline Corner Phone +1 415 202 5678 caroline.corner@westwicke.com **AVITA Medical Ltd** David McIntyre Chief Financial Officer Phone +1 661 367 9178 dmcintyre@avitamedical.com

Important Safety Information

INDICATIONS FOR USE: The RECELL® Autologous Cell Harvesting Device is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older. The RECELL device is used by an appropriately-licensed healthcare professional at the patient's point of care to prepare autologous RES® Regenerative Epidermal Suspension for direct application to acute partial-thickness thermal burn wounds or application in combination with meshed autografting for acute full-thickness thermal burn wounds. **CONTRAINDICATIONS:** RECELL is contraindicated for: the treatment of wounds clinically diagnosed as infected or with necrotic tissue, the treatment of patients with a known hypersensitivity to trypsin or compound sodium lactate (Hartmann's) solution, patients having a known hypersensitivity to anesthetics, adrenaline/epinephrine, povidone-iodine, or chlorhexidine solutions. **WARNINGS:** Autologous use only. Wound beds treated with a cytotoxic agent (e.g., silver sulfadiazine) should be rinsed prior to application of the cell suspension. RECELL is provided sterile and is intended for single-use. Do not use if packaging is damaged or expired. Choose a donor site with no evidence of cellulitis or infection and process skin immediately. A skin sample should require between 15 and 30 minutes contact with Enzyme. Contact in excess of 60 minutes is not recommended. RECELL Enzyme is animal derived and freedom from infectious agents cannot be guaranteed. **PRECAUTIONS:** RECELL is not intended for use without meshed autograft for treatment of full-thickness burn wounds. The safety and effectiveness of RECELL without meshed autograft have not been established for treatment of partial-thickness burn wounds: on the hands and articulating joints, >320 cm^2, in patients with wounds totaling >20% total body surface area (TBSA). The safety and effectiveness of RECELL with autografting have not been established for treatment of full-thickness burn wounds: on the hands and articulated joints, in patients with wounds totaling >50% TBSA. **SPECIAL PATIENT POPULATIONS:** The safety and effectiveness of RECELL have not been established for treatment of acute thermal partial-thickness or full-thickness burn wounds in pediatric patients younger than 18 years of age.

For complete Important Safety Information, refer to Instructions For Use, available at RECELLsystem.com

---

[i] Holmes JH, Molnar JA, Carter JE, et al. A comparative study of the RECELL® device and autologous split-thickness meshed skin graft in the treatment of acute burn injuries. J Burn Care Res. 2018

[ii] Holmes JH, Molnar JA, Shupp JW, et al. Demonstration of the safety and effectiveness of the RECELL System combined with split-thickness meshed autografts for the reduction of donor skin to treat mixed-depth burn injuries. Burns. 2019;45:772-782

[iii] Kowal, S., Kruger, E., Bilir, P. et al. Cost-Effectiveness of the Use of Autologous Cell Harvesting Device Compared to Standard of Care for Treatment of Severe Burns in the United States. Advances in Therapy. (May 2019). https://doi.org/10.1007/s12325-019-00961-2

[iv] American Burn Association NBR Advisory Committee, National Burn Repository 2016 Report

[v] Advances in Vitiligo: An Update on Medical and Surgical Treatments. A. Dillon, et al. J Clin Aesth Derm. 2017

[vi] Willingness-to-pay and quality of life in patients with vitiligo. Radtke, et al. BJD. 2009